February 15, 2024

Central Japan Railway Company
West Japan Railway Company
AstraZeneca K.K.

Launch of a Service to Achieve Net Zero CO2 Emissions on the Tokaido and SanyoShinkansen
Central Japan Railway Company (President and Representative Director: Shunsuke Niwa; hereinafterreferred to as “JR Central”) and West Japan Railway Company (President and Representative Director: Kazuaki
Hasegawa; hereinafter referred to as “JR West”) are committed to creating a sustainable society through global
environmental conservation. With the aim of realizing this, the two companies have considered providing thecorporate members of the EX Reservation Service with a service that uses CO2-free electricity to achieve net
zero CO2 emissions associated with traveling on the Shinkansen, which will be the first of its kind in Japan, andhave worked with AstraZeneca K.K. (President and Representative Director: Takafumi Horii; hereinafterreferred to as “AstraZeneca”) as a partner. We would like to inform you that we have decided to start theservice.
By rolling out this service, we will create an environment where customers who are interested in preserving
the global environment can use the Tokaido and Sanyo Shinkansen with greater peace of mind.
1. Service Overview (See Attachment 1 for details.)(1) Scheme: ① JR Central and JR West purchase CO2-free electricity* from power companies.
② CO2-free electricity is allocated to business trips by the corporate members of the EX
Reservation Service.
(The corporate members of the EX Reservation Service pay additional charges for purchasing CO2free electricity.)③ JR Central and JR West issue a certificate that validates CO2 reduction effects to the corporate
members of the EX Reservation Service.
* CO2-free electricity: Electricity with a non-fossil certificate that is derived from renewable energy
sources, such as solar power generation, that do not emit CO2 during power generation(2) Start Date: April 2024
(3) Benefits : Net zero CO2 emissions (Scope 3*) associated with the use of the Tokaido and Sanyo
Shinkansen by the corporate members of the Express Reservation Service* Scope 3: CO2 emissions of other companies related to business activities
2. Background to This Collaboration
JR Central and JR West have worked to reduce CO2 emissions associated with railway travel and topromote understanding of the environmental superiority of railways through efforts such as publishing CO2
emissions between each station on the Tokaido and Sanyo Shinkansen.
AstraZeneca, a corporate member of the EX Express Service, is a global science-led biopharmaceuticalcompany. With the belief that the health of society and the planet is essential to achieving people’s health,it has positioned evidence-based environmental measures as a strategic priority. Domestically, since 2019,it has worked on CO2 emission countermeasures for the travel of employees and has adopted the conceptof a CO2 budget* for business trips. In this process, each company came to a consensus regarding theirinitiatives, and it was decided that the three companies would work together to create a scheme for thisservice.
* CO2 budget: Concept of setting an upper limit on CO2 emissions associated with business trips* See Attachment 2 for details of AstraZeneca’s environmental conservation efforts.

3. Contact regarding This Service
JR Central EX Reservation Sales Promotion Group tokyo-sales@jr-central.co.jp

Attachment 1

Launch of a Service to Achieve Net Zero CO2Emissions on the Tokaido and Sanyo Shinkansen<Service Scheme (image)>③ Provision of travel services
with net zero CO2 emissions
on the Tokaido and Sanyo
Shinkansen②Corporate
Members

Supply of CO2-freeelectricity (substantialrenewable electricity)⑤

Issuance of acertificate thatvalidates CO2
reduction effects④ Use of travel services with net
zero CO2 emissions for businesstrips on the Tokaido and Sanyo
Shinkansen (Payment ofadditional fees)①
Purchase of
CO2-freeelectricity

PowerCompanies

Attachment 2

AstraZeneca K.K.

AstraZeneca is a global, science-led biopharmaceutical company. In Japan, it works to further
contribute to the health of patients and the development of medical care, mainly focusing on cancer,
cardiovascular/renal/metabolic diseases, respiratory/immune diseases, and vaccines/immunotherapy.
Comment from Takafumi Horii
President and Representative Director,AstraZeneca K.K.
Company Profile● Head Office: Osaka City, Osaka Prefecture● Inauguration: January 2000

● Sales in 2022: $4,110 million1● Number of employees: Approximately 3,600
peopleAstraZeneca’s Commitment toDecarbonization“Climate change is said to be one of the largest public healthcrises of the 21st century. Climate change-related deaths
are expected to exceed those caused by COVID-19. 2 To
confront this crisis, society as a whole must work together tomake significant changes.
We believe that it is essential to work on reducing CO2emissions, and that companies need to take a moreproactive approach. We hope that this scheme willcontribute to the promotion of Scope3 reduction and theestablishment of a new standard for corporate
environmental conservation."With the belief that “the health of society and the planet is essential to achieving people’s health,” AstraZeneca promotes initiatives basedon scientific evidence on a global scale, aiming to be carbon negative by 2030 and achieve net zero CO2 emissions by 2045.
Initiatives as a Pioneer in Decarbonization in Japan
Scope 1 (direct CO2 emissions from the company) ): The largest-scale introduction of battery electric vehicles (BEVs) in Japan(approximately 60%)
Scope 2 (indirect CO2 emissions associated with the use of supplied electricity, etc.):• Completed conversion to substantial renewable energy at all domestic sites (by the end of 2022)
Scope 3 (CO2 emissions of other companies related to business activities):• In 2019, “Smart Travel” was introduced to switch from airplanes to the Shinkansen for business trips between Tokyo and Osaka.
• The introduction of the new scheme jointly with Central Japan Railway Company and West Japan Railway Company will reduce CO 2
emissions by an estimated 184 tons between Tokyo and Hakata on the Tokaido and Sanyo Shinkansen.

1. Including revenue from Alexion Pharmaceutical’s Rare Disease Department
2. In the case of calculating and comparing the number of deaths by year based on the United Nations’ climate change-related deaths (https://www.un.org/sites/un2.un.org/files/2021/08/fastfacts-health.pdf) and the cumulative death toll data from the WHO
Coronavirus (COVID-19) Dashboard (https://covid19.who.int/)